Category Archives: Hormone Replacement Therapy

Hormone replacement therapy (HRT) tablets marketis expected to rise with a substantial CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the increased development of drugs with better therapeutic profiles. The report contains data of the base year 2018 and historic year 2017.

The universal Hormone Replacement Therapy (HRT) Tablets market report is produced by performing high level market research analysis of key marketplace segments to identify opportunities, challenges, drivers, and market structures for our clients. This market report potentially presents with the numerous insights and business solutions that will help to stay ahead of the competition. Being a wide-ranging market research report, it is sure to help grow business in several ways. An influential Hormone Replacement Therapy (HRT) Tablets market report assists in determining and optimizing each stage in the lifecycle of industrial process that includes engagement, acquisition, retention, and monetization.

Get Sample Copy Of This Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hormone-replacement-therapy-hrt-tablets-market

Few of the major competitors currently working in the global hormone replacement therapy (HRT) tablets market areALLERGAN, Novo Nordisk A/S, Sanofi, Abbott, TherapeuticsMD, Inc., Mithra Pharmaceuticals among others.

Key Development in the Market:

Table of Contents

1. Introduction2. Market Segmentation3. Market Overview4. Executive Summary5. Premium Insights6. Global, By Component7. Product Type8. Delivery9. Industry Type10. Geography

Get Full Table Of content @https://www.databridgemarketresearch.com/toc/?dbmr=global-hormone-replacement-therapy-hrt-tablets-market

Segmentation: Global Hormone Replacement Therapy (HRT) Tablets Market

By Type of Disease

By Treatment Type

By End-User

By Distribution Channel

By Geography

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hormone-replacement-therapy-hrt-tablets-market

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:Corporatesales@databridgemarketresearch.com

Read the rest here:
Global Hormone Replacement Therapy (HRT) Tablets Market Will Experience A Noticeable Growth During The Forecast Period 2019-2026||ALLERGAN, Novo...

ANN ARBOR, Mich.--(BUSINESS WIRE)--Nov 9, 2020--

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended September 30, 2020.

We continue to advance MLE-301 as a potential alternative to hormone replacement therapy for the treatment of vasomotor symptoms (VMS) related to menopause, and were pleased to initiate our Phase 1 clinical trial in the 3rd quarter, said Julia C. Owens, President and Chief Executive Officer of Millendo Therapeutics. MLE-301 is a priority program for Millendo, given the broader industry excitement around its potential to address a large unmet need, along with a refocusing of our internal pipeline efforts. With over 20 million women in the United States suffering from menopausal VMS, and with symptoms lasting on average over seven years, there is still a critical need for a treatment that has the efficacy of hormone replacement therapy without increased risks of cancer or cardiovascular disease."

Third Quarter 2020 and Recent Highlights

Third Quarter 2020 Financial Results

Cash Position: Cash, cash equivalents and restricted cash were $43.8 million at September 30, 2020, compared to $63.5 million at December 31, 2019.

Research and Development (R&D) Expenses: R&D expenses were $2.7 million for the third quarter 2020, as compared to $7.3 million for the same period in 2019. The decrease in R&D expenses was primarily driven by decreased spend due to discontinuing our development of the livoletide program and ceasing investing in the nevanimibe program, offset by increased spend on MLE-301.

General and Administrative (G&A) Expenses: G&A expenses were $3.4 million for the third quarter 2020, as compared to $4.4 million for the same period in 2019. The decrease in G&A expenses was primarily driven by decreased professional fees as a result of lower accounting and consulting fees incurred as compared to the prior period. Compensation and stock-based compensation decreased as a result of a decrease in our general and administrative headcount and changes to compensation arrangements.

Net Loss: The companys net loss for the quarter ended September 30, 2020 was $6.4 million as compared to $11.6 million for the same period in 2019.

2020 Financial Guidance

Millendo expects that its cash, cash equivalents and restricted cash will support its current development and operational plans into 2022.

About MLE-301

MLE-301 is a neurokinin 3 receptor (NK3R) antagonist that is being developed as a potential treatment of vasomotor symptoms (VMS), commonly known as hot flashes and night sweats, in menopausal women. NK3R plays a key role in regulating the activity of KNDy (kisspeptin/NKB/dynorphin) neurons, which has been shown to participate in the generation of VMS. By inhibiting the NK3R signaling on the KNDy neurons and potentially other NK3R-expressing neurons that propagate heat dissipation signals through the hypothalamus, MLE-301 aims to reduce the effects of hyperactive KNDy neurons and thereby decrease the frequency and severity of vasomotor symptoms.

About Millendo Therapeutics, Inc.

Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit http://www.millendo.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the words may, might, will, could, would, should, expect, intend, plan, objective, anticipate, believe, estimate, predict, project, potential, continue and ongoing, or the negative of these terms, or other comparable terminology intended to identify statements about the future. These include statements with respect to the Phase 1 clinical trials for and the potential clinical impact of MLE-301 on menopausal vasomotor symptoms and the companys ongoing strategic review of its pipeline, and, therefore, you are cautioned not to place undue reliance on them. Such forward-looking statements are based on Millendos expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including that Millendo has incurred significant losses since inception, Millendo has a limited operating history and has never generated any revenue from product sales, Millendo will require additional capital to finance its operations, Millendo's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Millendo's clinical trials may not support Millendo's product candidate claims, Millendo may encounter substantial delays in its clinical trials or Millendo may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Millendo's control, Millendo's product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Millendo faces substantial competition and Millendos business, preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic. You should refer to the risk factor disclosure set forth in the periodic reports and other documents Millendo files with the Securities and Exchange Commission available at http://www.sec.gov, including without limitation Millendos Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020.

New factors emerge from time to time and it is not possible for Millendo to predict all such factors, nor can Millendo assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to Millendo as of the date of this press release. Millendo disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

Three Months Ended

Nine Months Ended

September 30,

September 30,

2020

2019

2020

2019

$

2,676

$

7,308

$

16,682

$

19,493

3,380

4,443

12,113

13,075

6,056

11,751

28,795

32,568

318

(119

)

249

(699

)

$

(6,374

)

$

(11,632

)

$

(29,044

)

$

(31,869

)

$

(0.34

)

$

(0.87

)

$

(1.54

)

Read more:
Millendo Therapeutics Reports Third Quarter 2020 Operating and Financial Results - The Baytown Sun

The globalHormone Replacement Therapymarket research report offers all the vital data in the domain. The latest report assists new bees as well as established market participants to analyze and predict the Hormone Replacement Therapy market at the regional as well as global level. It covers the volume [k MT] as well as revenues [USD Million] of the global Hormone Replacement Therapy market for the estimated period. Numerous key players Pfizer, Abbott Laboratories, Novo Nordisk, Mylan Laboratories, Eli Lilly, Novartis, Roche, Bayer Healthcare, Merck Serono, Genentech are dominating the global Hormone Replacement Therapy market. These players hold the majority of share of the global Hormone Replacement Therapy market.

Sample of global Hormone Replacement Therapy Market Report at::https://www.marketresearchstore.com/report/global-hormone-replacement-therapy-market-report-2020-industry-757683#RequestSample

The data presented in the global Hormone Replacement Therapy market offers budding opportunities, which help users to make strategic moves and prosper their business. The report highlights the impact of numerous factors that might result in obstructing or propelling the Hormone Replacement Therapy market at global as well as local level. The global Hormone Replacement Therapy market research report offers the summary of key players dominating the market including several aspects such as their financial summary, business strategy, and most recent developments in these firms.

Key points of the global Hormone Replacement Therapy market

Theoretical analysis of the global Hormone Replacement Therapy market stimulators, products, and other vital facets Recent, historical, and future trends in terms of revenue and market dynamics are reported Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow Future market trends, latest innovations, and various business strategies are reported Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The global Hormone Replacement Therapy market research report offers users with an all-inclusive package of market analysis that includes current market size, expansion rate, and value chain analysis. The global Hormone Replacement Therapy market is segmented on a regional basis Europe, North America, Latin America, Asia Pacific, and Middle East & Africa as well. To offer a comprehensive view and competitive outlook of the global Hormone Replacement Therapy market, our review team employs numerous methodological procedures, for instance, Porters five forces analysis.

Ask Any Kind of Query Before Purchasing the Report Here::https://www.marketresearchstore.com/report/global-hormone-replacement-therapy-market-report-2020-industry-757683#InquiryForBuying

This research report includes the analysis of various Hormone Replacement Therapy market segments {Human Growth Hormone Therapies, Estrogen, Testosterone, Thyroid Hormones}; {Menopause, Male Hypogonadism, Hypothyroidism, Growth Hormone Deficiency, Others}. The bifurcation of the global market is done based on its present and prospective inclinations. The regional bifurcation involves the present market scenario in the region along with the future projection of the global Hormone Replacement Therapy market. The global market report offers an overview of expected market conditions due to changes in the technological, topographical, and economic elements.

Questions answered in the report include

1. What is the expected market size by the end of the forecast period?2. What are the major factors initiating the global Hormone Replacement Therapy market growth?3. What are the latest developments and trending market strategies that are influencing the growth of the Hormone Replacement Therapy market?4. What are the key outcomes of the Hormone Replacement Therapy market developments?5. Who are the key players in the market?6. What are the opportunities and challenges faced by the key players?

Read Detailed Index of full Research Study at:https://www.marketresearchstore.com/report/global-hormone-replacement-therapy-market-report-2020-industry-757683

Key Reasons for Purchasing Global Hormone Replacement Therapy Market Report

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities

See more here:
Global Hormone Replacement Therapy Market Recent Trends, Development, Growth and Forecast 2020-2027 - Eurowire

The global Hormone Replacement Therapy market is predicted to show promising growth during the forecast period of 2018 to 2028, according to the latest research report published by Fact.MR. The study highlights that the market for a Hormone Replacement Therapy is likely to grow at a stupendous pace on the back of ongoing research and development activities and technological developments in this market the during assessment period.

This report includes reliable data on drivers, restraints, challenges, threats, and growth opportunities in the market for the Hormone Replacement Therapy. Thus, it covers a detailed analysis on all key factors responsible for the growth of the overall Hormone Replacement Therapy market during the assessment period. Apart from this, the report provides an analysis of new revenue streams in the Hormone Replacement Therapy market. The data presented in this report helps vendors in deciding their business strategies to gain prominent revenues.

The recent COVID-19 outbreak has disrupted almost every field. The latest report on the Hormone Replacement Therapy market provides exclusive data on the impact of the COVID-19 pandemic on this market. In addition to this, the study sheds light on various tactics utilized by industry leaders to come out of this critical scenario and run their businesses successfully during and post-pandemic period.

Request to View Sample of Research Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2224

The study depicted in the report on the global Hormone Replacement Therapy market help readers understands the demand patterns of different end-users. This aside, it provides data on historical as well as latest trends in the market for the Hormone Replacement Therapy. Apart from this, it foretells potential trends and investment avenues in the Hormone Replacement Therapy market from 2018 to 2028.

Based on product types, the Hormone Replacement Therapy market report presents insight into key adoption trends for the following segments:

The assessment presents volume, shares, and revenues of the Hormone Replacement Therapy market during the tenure of 2018 to 2028. In addition to this, the study sheds light on changing market size, revenue, and share of important product segments in the global Hormone Replacement Therapy market during this period. Analysts at Fact.MR give prominent data on recent technological developments and product developments in the market during the assessment period.

To give an understanding of potential avenues in the global Hormone Replacement Therapy market, the latest report provides trustworthy data on new avenues and opportunities in the following segments:

This study provides important data on key players and the competitive landscape of the Hormone Replacement Therapy market. Apart from this, it presents an analysis of diverse organic as well as inorganic strategies used by industry leaders to maintain their prominent position in the market for the Hormone Replacement Therapy. Thus, the report includes the study and impact of all strategies such as mergers, acquisitions, partnerships, collaboration agreements, and joint ventures in the market for Hormone Replacement Therapy during the assessment period.

The list of important players profiled in the report on global Hormone Replacement Therapy market includes:

The study provides a study of key growth opportunities in diverse geographical regions. It also includes regulatory aspects and purchasing patterns of consumers from different geographical regions. Thus, the data presented in this report helps users to decide their strategies while expanding their businesses in those specific geographies.

The geographical regions studied in the report on the global Hormone Replacement Therapy market are:

To Know More Information about This Report, Ask The Analyst @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=2224

Reasons to choose a Fact.MR:

And many more

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Press Release: https://www.factmr.com/media-release/719/hormone-replacement-therapy-market

See more here:
Hormone Replacement Therapy Market to Witness Positive Growth owing to Outbreak of COVID-19, Projects Fact.MR - The Cloud Tribune

The aim of this detailed market research report on Hormone Replacement Therapy market is to offer readers, with ample competitive edge in the context of market dynamics such as challenges, barriers, threats and opportunities that orchestrate high end growth amidst stringent competition in global Hormone Replacement Therapy market.

Get PDF Sample Copy of this Report to understand the structure of the complete report: https://www.orbispharmareports.com/sample-request/57999

Global Hormone Replacement Therapy Market: Understanding Scope:

The aforementioned Hormone Replacement Therapy market has been evaluated to register a thumping growth of xx million USD in 2020 and is anticipated to further attain a growth valuation of xx million USD through the forecast tenure till 2027, growing at a CAGR of xx% throughout the forecast span.For utmost reader convenience this elaborate research report on global Hormone Replacement Therapy market identifies 2019 as the base year and 2020-27 constitutes the overall forecast tenure, allowing precise market estimation about growth probabilities in the Hormone Replacement Therapy market.

Major Company Profiles operating in the Hormone Replacement Therapy Market:

Eli LillyTevaNovo NordiskPfizerBayerAbbVieAbbottMylanMerck KGaANovartisTherapeuticsMDRocheANI PharmaceuticalsEndo InternationalIpsen

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.orbispharmareports.com/enquiry-before-buying/57999

Unravelling Report Offerings Market:

1. A thorough and detailed analytical review of the Hormone Replacement Therapy market2. Brief about evident changes and market developments affecting market dynamics3. A clear understanding of market segmentation related to Hormone Replacement Therapy market4. A critical synopsis of all historical, real time as well as forecast developments likely to impact growth5. A systematic review of the diverse market developments and potent alterations that steer growth in the global Hormone Replacement Therapy market6. A reference of all the successful growth rendering developments

By the product type, the market is primarily split into:

Estrogen HormoneGrowth HormoneThyroid HormoneTestosterone Hormone

By the application, this report covers the following segments:

MenopauseHypothyroidismGrowth Hormone DeficiencyMale HypogonadismOther Diseases

Owing to the sudden onset of global pandemic with the COVID-19 outrage in place, Orbis Pharma Reports analysts and dedicated research personnel have assigned a specific section evaluating the various implications and explaining the aftermath of the pandemic affecting diverse trends, developments as well as also categorically focusing on various opportunities emerging during the pandemic. The section is aimed at allowing market players to devise winning growth plans to secure profit even amidst the pandemic in Hormone Replacement Therapy market.

We are a team of young, mindful, agile research experts who pursue a fact-based approach to decode all relevant market specific information, required to harness superlative reader understanding about various marker facets that lead towards unhindered growth prognosis. Our flagship expertise in scavenging through various facets of market development and key perspectives are in place to unleash industry patterns to design and develop a future-ready market study that unravels information based on which report readers can well devise profit oriented business decisions that fetch highly profitable investment returns, favoring market participants.At Orbis Pharma Reports we categorically offer expert market research-oriented services across a heterogenous range of industrial participants, such as manufacturing companies, corporations, product development companies, who stand in greater need of market specific information.

Browse Full Report at: https://www.orbispharmareports.com/covid-19-impact-on-global-hormone-replacement-therapy-industry-research-report-2020-segmented-by-major-market-players-types-applications-and-countries-forecast-to-2026/

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

Read more from the original source:
Covid-19 Impact on Global Hormone Replacement Therapy Market Growth Opportunities, Revenue, Industry Analysis and Forecasts 2026 - TechnoWeekly

For the most part, being a woman gives you an upper hand if you get diagnosed with coronavirus.

Research shows women are less likely to become severely ill or die from the disease.

It's unclear exactly why our biological sex might make us more or less resilient, but females tend to have more robust immune responses, and sex hormones are thought to play a role.

There is, however, one way in which hormones specifically oestrogen may increase the risk of COVID-19 complications.

According to new guidelines from the Royal Australian College of General Practitioners (RACGP), women who have been severely ill with COVID-19 should stop using combined hormonal contraception.

That's because COVID-19 can increase the risk of blood clotting a risk that's already heightened with the use of hormonal contraceptives that contain oestrogen (which make blood clots more likely).

So what does the risk of clotting mean for other women taking oestrogen-containing medicine, or for those who are pregnant?

First up, it's important to note that the new guidance only applies to people on birth control who have been severely ill with COVID-19 those who had an acute infection and/or developed severe post-COVID-19 illness.

"This is a cautionary piece of advice to be aware that people might be at an increased risk of blood clots if they've had these severe infections," said Amy Moten, chair of the RACGP's special interest group on sexual health medicine.

"We're now seeing potential long-term consequences ... and one of them appears to be that people with more serious episodes of COVID-19 have an increased risk of blood clotting."

So far, there is no evidence to suggest COVID-19-related blood clotting is occurring more frequently in women on birth control, or among women who are pregnant or using hormone therapy (both of which increase levels of oestrogen).

Under normal circumstances, the absolute risk of getting a blood clot while taking the pill is extremely low.

"Around two to four people out of 10,000 over one year might develop a blood clot. For people on the pill, the risk might be around double that," Dr Moten said.

The risk can depend on the type of pill and the dose of oestrogen and progesterone.

There are also other known risks for blood clots and their complications.

"Whether you have a strong family history of someone having a blood clot, people with a high BMI, people who smoke, particularly over the age of 35, all have independent risk factors for blood clotting," Dr Moten said.

For women who have had an asymptomatic or mild case of coronavirus and use combined hormonal contraception, there is no reason to stop using or switch contraceptives.

If GPs do advise people to stop taking a combined hormonal contraceptive, Dr Moten said they should transition the patient onto something like a progesterone-only contraception or a barrier method.

Progesterone-only contraceptives include intrauterine devices (IUDs, sometimes known by the brand name 'Mirena'), the contraceptive implant (sometimes known by the brand name 'Implanon'), the contraceptive injection, and the progesterone-only pill (sometimes known as the 'mini pill').

"These are all very established to be safe in people who have risk factors for blood clots, and so the advice for COVID-19 doesn't apply to this progesterone-only contraception," she said.

Hormone replacement therapy or HRT is a medication containing the hormones that a woman's body stops producing after menopause. It's used to treat menopausal symptoms.

Dr Moten said although there were some situations in which HRT may be inadvisable, a COVID-19 diagnosis wasn't one of them.

"It is a lower risk overall because of the dose and types of oestrogen involved in those particular medications," she said.

"There are some kinds of oestrogen-only menopause hormone therapies that don't have any increased risk of [blood clotting]."

Breaking down the latest news and research to understand how the world is living through an epidemic, this is the ABC's Coronacast podcast.

Pregnancy causes major fluctuations in hormone production, and, in general, pregnant women are at an increased risk of blood clotting.

According to Australia's National COVID-19 Clinical Evidence Taskforce, hospitalised pregnant women with an acute infection, such as COVID-19, are at an even greater risk.

But endocrinologist and professor of women's health Susan Davis said the jury was still out on the risks of COVID-19 in pregnancy.

"Although women who are pregnant are not highly protected against getting infected, they appear to be relatively protected from severe COVID-19," said Professor Davis of Monash University.

"There's not a lot of data the number of studies that have looked fully at pregnant women is small.

"But it appears that either there is no increase in adverse effects in pregnant women, or [that] pregnancy may be protective."

While increased levels of oestrogen in the body (from medication) can increase the risk of blood clotting, naturally occurring oestrogen can also have a protective effect.

"The pill is different [it] contains a synthetic oestrogen, which is far more potent than the one our body makes," Professor Davis said.

Get the latest health news and information from across the ABC.

Naturally occurring oestrogen may actually help women to mount an immune response to COVID-19.

"COVID-19 gains entry into cells through a receptor called ACE-2," Professor Davis said.

"It can be activated in ways that heighten inflammation or in ways that suppress inflammation.

"By chance, oestrogen also activates ACE-2 but triggers the path that's anti-inflammatory."

In many cases, people who become severely unwell or die from COVID-19 do so because of an overactive, hyper-inflammatory response to the virus.

"Oestrogen and progesterone dampen down the inflammatory immune response," Professor Davis said.

While biological sex differences may impact a person's vulnerability to COVID-19, the better survival rates among women over the age of 80 when hormone levels in both sexes equalise suggest sex hormones are not the only factor contributing to different mortality rates.

Read more here:
Pregnant or taking the pill? Here's what to know about COVID-19, blood clots and hormones - ABC News

Prostate cancer hormone replacement therapy is also known as androgen deprivation therapy. The primary goal of prostrate hormone replacement therapy is to stop male hormones androgen from affecting prostate cancer cells. Androgen are responsible for stimulating prostate cancer cell to proliferate. Thus, lowering the levels of androgen by using prostate cancer hormone replacement products will make the cancerous cells to shrink and proliferate slowly over the time. However, prostate cancer hormone replacement therapy alone does not cure prostate cancer. In the treatment market of prostate cancer hormone replacement, the luteinizing hormone-releasing hormone (LHRH) agonists are slowly replacing surgical orchiectomy procedures across the globe. Besides, more recent advances these prostate cancer hormone have focused on increased durational activity. Furthermore, a 12thmonth preparations are also readily available in the of prostate cancer hormone replacement market.

New advancements in prostate cancer hormone replacement therapies for management of prostate cancer is anticipated the drive the of prostate cancer hormone replacement market growth. Besides, global increase in the incidence of prostate cancer will drive the of prostate cancer hormone replacement market growth. According to American Cancer Society estimates, number of people diagnosed with prostate cancer in the United States for 2019 were 174,650 and about 31,620 deaths occurred due to this disease. The increase demand for treatment of prostate cancer using prostate cancer hormone replacement therapy will drive the of prostate cancer hormone replacement market. Besides, availability of cost-affordable hormonal therapies will also drive the prostate cancer hormone replacement market growth. However, less number of commercially available drugs and treatments for prostate cancer may restrain the of prostate cancer hormone replacement market growth.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/29413

The global Prostate cancer hormone replacement market is segmented on the basis of product, modality, application and end user

On the basis of types of hormone therapy, the global prostate cancer hormone replacement Device devices market is segmented into:

On the basis of Distribution Channels, the global Prostate cancer hormone replacement Device is segmented into:

Many prostate cancer hormone replacement therapies which are directed for treating prostate carcinoma are generally initiated early because major complications could significantly get reduced. Many studies have clearly mentioned that the prostate cancer develops from the androgen-dependent epithelium and also sensitive enough for withdrawal of androgen in its early stages. However, with onset of prostate cancer hormone replacement products, it has been possible to lower androgen levels significantly. Furthermore, with application of prostate cancer hormone replacement products, virtually all the prostate cancer are able to respond to androgen deprivation.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/29413

On the basis of region, the global prostate cancer hormone replacement market can be segmented into five key geographies: North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa. North America is expected to dominate the global prostate cancer hormone replacement market with largest revenue share. The regions dominance is attributed majorly due to the growing prostate cancer patients. Europe which also aggressively invests in healthcare, is also expected to contribute significantly to the prostate cancer hormone replacement market share. High rate of adaptation towards epidural procedures in hospital and ambulatory surgical centers across Europe can be anticipated to push the prostate cancer hormone replacement growth in the region. From East and South Asia, China and India respectively, are expected to register the fastest growth during the forecast period, whereas Brazil and Mexico from Latin America are also anticipated to contribute significantly to the prostate cancer hormone replacement market. The key factor to the regions of prostate cancer hormone replacement market growth in prostate cancer hormone replacement is mainly due to rise in healthcare awareness amongst the people and augmented disposable income. MEA is expected to grow at an average rate (in the usage of prostate cancer hormone replacement) in the forecast period.

Some of the market players in prostate cancer hormone replacement products globally include Johnson & Johnson; Astella, Inc.; Sanofi; Ipsen; Bayer AG; AstraZeneca; Valeant Pharmaceuticals North America LLC (Dendreon Corporation), AB Science, AbbVie, Advantagene, Amgen, Aptevo Therapeutics, Asana BioSciences, Astellas and AstraZeneca.

You Can Request for TOC[emailprotected]

https://www.persistencemarketresearch.com/toc/29413

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Read the rest here:
The Prostate Cancer Hormone Replacement market to be in conjunction to growth from 2019 to 2029 - KYT24

Health experts say roughly 1.3 million women in the U.S. become menopausal each year, usually between the ages of 40 and 50.

BRIDGTON, Maine Menopause is a time when menstrual periods cease over a 12 month spana big change that can be full of mystery, stress, and a little fear. Another concern is that many parents aren't comfortable talking about menopause to their doctors or anyone else.

Lois McIver was in her late forties when she began experiencing debilitating migraines. They subsided after her doctor recommended birth control pills. Not too long after she got off of them in her mid-50's, a new set of symptoms came all at once.

"Six months later no periods, hot flashes daily like twenty times a day," McIver said.

McIver, who has three grown daughters, was going through perimenopause, a transitional stage when the body is preparing to stop ovulating. The birth control pills may have put off what was inevitable.

"There is nothing out there to prepare you that this might happen and what you may go through," McIver said.

Dr. Rebecca Whiteley is a OBGYN at Northern Light Mercy Women's Health. She says menopause is only one day in a woman's life, which is exactly when she has not had a period for 12 months. But it can be a moving target.

"The average age for menopause is 51. But you know some people start in their early 40's, some in their 50's," Dr. Whiteley said.

Some women can even start earlier, in their 30's. Experts list 34 different symptoms which can effect a woman years before menopause actually begins. Hot flashes affect around 75% of menopausal women.

Other more common symptoms include fatigue, irregular periods, night sweats, mood swings, sleep disorders, and memory problems. All are the result of dropping estrogen levels, but some women don't get any symptoms.

In some cases, doctors may prescribe hormone replacement therapy, known as HRT, to supplement estrogen levels. There are other options to help take the edge off the hot flashes, including anti-depressants and blood pressure medication.

If you are suffering with symptoms you also may want to seek out a women's health care provider.

"If you feel you aren't getting anywhere with your primary care doctor, don't stop there. Most people can in to see a gynecologist without necessarily needing a referral," Dr. Whiteley said.

As for McIver, hormone replacement therapy was not an option because the treatment carries an increased risk for breast cancer and the disease runs in her family. With the support of her husband, she stayed active and took care of herself.

Except for an occasional hot flash, McIver is now on the other side. She encourages other women to find out everything they can about perimenopause, so they can make the transition more manageable.

For more information on menopause, symptoms, and treatment, click HERE.

Continue reading here:
Unraveling the mystery and symptoms of menopause - NewsCenterMaine.com WCSH-WLBZ

A new study, led by experts at the Universities of Nottingham and Oxford, provides a clearer and more detailed picture on which women are at increased risk of breast cancer when using different HRT treatments.

The results of the study, published in The BMJ, confirm that HRT use is associated with increased risks of breast cancer, particularly for older women. However, it also suggests that for longer term HRT use the increased risks are lower than those reported in a recent meta-analysis, which combined the results of 24 varied studies.

The study also shows a more noticeable decline in increased risk once HRT has stopped, again when compared to the same meta-analysis.

Hormone replacement therapy (HRT) can be a significant benefit to women who suffer severe symptoms during menopause. Up to 80% of women experience some unpleasant symptoms such as hot flushes, night sweats, mood changes or memory and concentration losses. Osteoporosis is also associated with menopause and, for a small proportion of women, symptoms can be disabling and affect their quality of life.

HRT treatments involve one or more of a class of hormonal drugs, with an oestrogen as the key component and a progestogen normally added to protect the womb. As with all drug treatments, HRT has side effects and an increase in risk of breast cancer is one these.

Whilst previous studies have looked at associations between HRT use and increased risks of breast cancer, the detailed evidence of the risk associations with hormones used in specific HRT treatments has been lacking.

Dr Yana Vinogradova, a Senior Research Fellow in the School of Medicine at the University of Nottingham is lead investigator on the study. She says: Our purpose was to conduct the largest observational study ever undertaken, and to include all available information on HRT use and other risk factors. Our aim was to provide comprehensive, detailed and accurate estimates of the risks for different HRT treatment formulations.

To carry out the study, the team extracted data over a twenty period between 1998 and 2018 from two of the largest UK primary care databases, covering 2000 GP surgeries. The team identified all women aged from 50 to 79 with a diagnosis for breast cancer, matching by age and general practice to controls with no breast cancer diagnosis. They then compared the HRT prescription records of all women who had developed breast cancer with those who had not, taking into account when and for how long patients had been using a treatment.

To investigate the relative safety of different treatments, all HRT treatments were included, with the hormones used in the treatments and the method of delivery (tablets, patches or creams) all being investigated.

The results showed that the increased risk of breast cancer was much higher for combined oestrogen-progestogen treatments than for oestrogen-only treatments. Risk also increased the longer patients used HRT. The increased risks diminished when HRT treatment stopped, disappearing completely for oestrogen-only users and for short-term users of combined treatments.

Our study has found that the level of increased breast cancer risk associated with HRT depends on a number of factors, which can be reduced by careful choice of treatment. This will be of particular benefit to women in their 70s, for whom the levels of increased risk are highest. Many women, however, may be reassured by the low levels of associated increased risk of breast cancer for them from the treatment they are using, said Dr Vinogradova.

These results provide clearer, more detailed, and more robust information for doctors and patients about the relative increases in risk of breast cancer for all HRT treatments used in the UK. They should both facilitate and increase confidence in treatment choices, and be useful in the development of best-practice guidelines, added Dr Vinogradova.

Read more from the original source:
Clearer picture on HRT & breast cancer - The Hippocratic Post

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

According to the latest market report published by Persistence Market Research titledCompounding Pharmacies Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,the global compounding pharmacies market is expected to expand at a CAGR of 7.5% during the forecast period 2017-2025.

The revision in the market size and forecasts have been carried out taking into account the impact of various macroeconomic indicators and other industry-based demand-driving factors, as well as the recent developments of key market participants.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/19396

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/19396

The globalcompounding pharmacies marketis projected to expand at a healthy CAGR of 7.5% in terms of value during the forecast period, revised from the previous CAGR of 4.4%, due to factors such as increasing medicinal droughts of prescription medicine across the globe, regarding which Persistence Market Research offers useful insights in detail in this report.

The primary factors driving revenue growth of the global compounding pharmacies market are increasing medicinal droughts of prescription medicine, growing demand for HRT drugs, and increase in demand for topical products these factors will upsurge the growth of the compounding pharmacies market in the coming years.

Increasing restricted formulations and unsafe compounding practices are some of the factors that will restrain the growth of the compounding pharmacies market over the forecast period.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/19396

Segmental Forecast of the Global Compounding Pharmacies Market

The market is segmented based on product type, application type, therapeutic area and region. On the basis of product type the market has been segmented as oral medication, topical medication, mouthwashes and suppositories.

By product type, the oral medication segment is expected to remain the largest segment, registering a CAGR of 9.5% in terms of value over the forecast period. The oral medication product type segment is expected to reach a market value of US$ 6,357.7 Mn by 2025 end.

On the basis of application type, the compounding pharmacies market has been segmented as

medication for adults, medication for veterinary, medication for children and medication for geriatric. The medication for adults segment is expected to remain the largest segment, registering a CAGR of 9.0% in terms of value over the forecast period. The medication for adults application type segment is expected to reach a market value of US$ 7,588.7 Mn by 2025 end.

On the basis of therapeutic area, the compounding pharmacies market has been segmented as pain management and hormone replacement therapy. By therapeutic area, hormone replacement therapy is expected to remain the largest segment, registering a CAGR of 9.9% in terms of value over the forecast period. The hormone replacement therapy segment is expected to reach a market value of US$ 9,380.7 Mn by 2025 end.

On the basis of region, the market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. North America dominated the global compounding pharmacies market with maximum value share of the overall market in 2016. The North America compounding pharmacies market is expected to register the highest CAGR of 7.6% over the forecast period to reach a market value of US$ 8,953.3 Mn by 2025 end.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

See more here:
The Compounding Pharmacies Market To Hit The 20/20 Vision With A CAGR Of 7.5% - Eurowire